Humana Inc.'s Stock Analysis

Humana Issues $1.5 Billion in Pre-Capitalized Trust Securities

Humana Inc. has entered into agreements to issue a total of 1.5 million Pre-Capitalized Trust Securities, generating $1.5 billion in capital. The funds will be used to provide the company with liquidity through the issuance of Senior Notes, which are due in 2036 and 2055. The P-Caps allow Humana to issue up to $750 million in Senior Notes to each of the two trusts involved, with specific conditions under which these rights can be exercised, including financial performance indicators and certain events of default.

The issued P-Caps will be mandatorily redeemed in 2036 and 2055 and are secured by U.S. Treasury securities. The company will incur semi-annual fees based on unexercised portions of its issuance rights. Additionally, the agreements impose various covenants and restrictions on Humana's ability to incur debt, merge, or sell significant assets, which could impact its financial flexibility. The securities were sold to qualified institutional buyers and are exempt from registration under the Securities Act.

May 19, 2026 16:30:11

Humana Reports Q1 2026 Financial Results and Guidance Update

Humana Inc. reported its financial results for the first quarter of 2026, showing earnings per share (EPS) of $9.83 on a GAAP basis and adjusted EPS of $10.31, which is at the high end of the company's guidance. The company affirmed its full-year 2026 adjusted EPS guidance of at least $9.00, while revising its GAAP EPS guidance down to at least $8.36. The insurance segment's GAAP benefit ratio was 89.4%, slightly better than expected, and Humana anticipates a 25% growth in individual Medicare Advantage membership compared to 2025. Strategic initiatives, including the integration of new contracts and growth in the CenterWell business, contributed to this growth.

Additionally, Humana announced a leadership transition within its insurance segment, with George Renaudin set to retire in June 2026. Aaron Martin will take over day-to-day management, while John Barger will lead Medicare Advantage operations. The company continues to face challenges, including a decline in Medicare Advantage star ratings, which could impact future revenues and quality bonus payments. Overall, Humana's strategic focus on customer experience and operational execution is aimed at supporting its growth and stability in the healthcare market.

Apr 29, 2026 06:06:00

Humana Annual Meeting Results and Shareholder Votes Summary

Humana Inc. held its annual meeting on April 16, 2026, with 107,941,773 shares represented by proxy, constituting a quorum. All ten nominees for the Board of Directors were elected, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026, was ratified. Additionally, shareholders approved a non-binding advisory vote on executive compensation and the Humana Inc. 2026 Stock Incentive Plan.

A shareholder proposal that aimed to require shareholder approval for excessive golden parachutes was not approved. The results indicate a supportive stance from shareholders on management's proposals and the board's composition, which may influence investor sentiment and stock performance.

Apr 20, 2026 16:31:18

Humana Elects New Board Member Robert S. Field

Humana Inc. has expanded its Board of Directors from ten to eleven members, electing Robert S. Field effective immediately after the 2026 Annual Meeting of Stockholders. Field qualifies as an independent director under NYSE standards and will be compensated according to the company's director compensation program, which includes the granting of restricted stock units. There are currently no arrangements or transactions involving Field that would present a material interest to the company.

Robert S. Field is the Principal and Managing Member of ηMed Capital Management LLC, focusing on U.S. healthcare services companies, particularly in managed care. His previous experience includes roles as a senior analyst at Luxor Capital and as an associate at McKinsey & Company. The appointment follows a thorough search process and reflects Humana's commitment to enhancing its Board and corporate governance, with input from shareholders.

Apr 10, 2026 16:32:11

Humana Completes $1 Billion Junior Subordinated Notes Offering

Humana Inc. has successfully completed a public offering of $1.0 billion in fixed-to-fixed rate junior subordinated notes due 2056, with an interest rate of 6.625%. The notes were sold at 100% of their principal amount, and the company expects to receive approximately $986 million in net proceeds after deducting underwriters’ fees and expenses. These proceeds are intended for general corporate purposes, including the repayment of existing debt.

The junior subordinated notes are unsecured and subordinate to the company's senior indebtedness, meaning they will be paid after senior obligations in the event of liquidation. Interest payments on these notes will be made semi-annually starting September 15, 2026, and the interest rate will reset every five years starting in 2031. The offering was managed by several financial institutions, including Goldman Sachs, J.P. Morgan, and Wells Fargo.

Mar 09, 2026 16:22:23

Humana Reaffirms FY 2026 Earnings Guidance for Investors

Humana Inc. plans to meet with investors and analysts from March 2 to March 31, 2026, where it will reaffirm its earnings guidance for the fiscal year 2026. The Company expects at least $8.89 in diluted earnings per share (EPS) and at least $9.00 in adjusted earnings per share (Adjusted EPS), consistent with previous guidance issued on February 11, 2026.

Management emphasizes the use of Adjusted EPS as a key measure to assess the Company’s core operating performance over time, although it should be considered alongside GAAP EPS. While Humana does not anticipate changes to its Adjusted EPS guidance, it acknowledges that potential adjustments to GAAP EPS may arise due to ongoing strategic initiatives.

Mar 02, 2026 07:30:07

Humana Reports Fourth Quarter 2025 Financial Results and Guidance

Humana Inc. reported a net loss per share of $6.61 for the fourth quarter of 2025, with an adjusted net loss per share of $3.96. For the full year 2025, the company recorded earnings per share (EPS) of $9.84 on a GAAP basis and $17.14 on an adjusted basis, aligning with management's expectations. The insurance segment's GAAP benefit ratio was 93.1% for the fourth quarter and 90.4% for the full year, slightly better than the guidance range. The company introduced its full year 2026 GAAP EPS guidance of at least $8.89, with an adjusted EPS of at least $9.00, anticipating a decline due to headwinds from Star Ratings for the upcoming year.

Additionally, Humana expects approximately 25% growth in individual Medicare Advantage membership in 2026, driven by new sales and improved retention strategies. The company also reported significant growth in its CenterWell and Medicaid platforms, with a 25% increase in patients in CenterWell Senior Primary Care during 2025. Humana's Medicaid services now operate in 13 states, with further expansion planned. Management has made prepared remarks available on the Investor Relations website, and a conference call is scheduled for analysts to discuss the financial results and future expectations.

Feb 11, 2026 06:40:24

Leadership Changes and Earnings Guidance Announced by Humana

Humana Inc. announced the retirement of George Renaudin, the Insurance Segment President, by the third quarter of 2026 after a 29-year career with the company. He will transition to an advisory role until the end of 2026, during which he will continue to receive his current salary and benefits. Aaron Martin will join the company in January 2026 as President of Medicare Advantage, and will succeed Renaudin as Insurance Segment President after his retirement. John Barger will be promoted to President of Medicare Advantage following Martin's appointment.

The company reaffirmed its earnings guidance for the year ending December 31, 2025, estimating approximately $12.26 in diluted earnings per share (EPS) and approximately $17.00 in adjusted earnings per share (Adjusted EPS). This guidance remains consistent with previous announcements, and the company does not expect changes to its Adjusted EPS guidance. However, potential changes to GAAP EPS guidance are anticipated due to ongoing strategic initiatives.

Dec 16, 2025 08:05:45

Humana Reaffirms Earnings Guidance for Fiscal Year 2025

Humana Inc. plans to meet with investors and analysts from December 1 to December 31, 2025, during which it will reaffirm its earnings guidance for the fiscal year 2025. The company expects approximately $12.26 in diluted earnings per share (EPS) and about $17.00 in adjusted earnings per share (Adjusted EPS), aligning with its previous guidance issued on November 5, 2025.

Management emphasizes that Adjusted EPS serves as a valuable measure for evaluating the company's core operating performance and is used for planning and incentive compensation decisions. While the Adjusted EPS guidance is not expected to change, potential adjustments to the GAAP EPS guidance may occur due to ongoing strategic initiatives and value creation efforts.

Dec 01, 2025 07:30:38

Humana Reports Q3 2025 Earnings and EPS Guidance Update

Humana Inc. reported its financial results for the third quarter of 2025, showing earnings per share (EPS) of $1.62 on a GAAP basis and $3.24 on an adjusted basis. Year-to-date EPS reached $16.43 on a GAAP basis and $21.10 on an adjusted basis. The insurance segment's benefit ratio was reported at 91.1%, aligning with company expectations. The company updated its full-year 2025 GAAP EPS guidance to approximately $12.26, down from the previous estimate of $13.77, while affirming its adjusted EPS guidance of approximately $17.00. Additionally, Humana anticipates a decline in individual Medicare Advantage membership of around 425,000 members, an improvement from earlier estimates of up to 500,000 members due to better retention and sales performance.

Humana is advancing its long-term strategy with growth in its CenterWell and Medicaid businesses, preparing for the launch of new dual eligible special needs plans in Michigan and Illinois. The company reported a 15% increase in patients within its CenterWell Primary Care segment compared to December 2024, alongside strong growth in CenterWell Pharmacy services. The company will hold a live question-and-answer session to discuss the financial results and future expectations, and further details can be accessed on its Investor Relations webpage.

Nov 05, 2025 06:11:16